Inhibiting the BCR signaling pathway with ibrutinib [70] or idelalisib [71] is known to impair BCR- and chemokine-mediated cell adhesion and migration in CLL. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.